Dechra Pharmaceuticals (DPH)

Sector:

Pharma and Biotech

Index:

FTSE 100

3,404.00p
   
  • Change Today:
    -62.00p
  • 52 Week High: 5,405.00
  • 52 Week Low: 3,110.00
  • Currency: UK Pounds
  • Shares Issued: 108.39m
  • Volume: 48,481
  • Market Cap: £3,689.69m
  • RiskGrade: 121

DPH Overview

Dechra Pharmaceuticals, founded in 1997 following a management buy-out from Lloyds Chemists, develops prescription only veterinary medicines for dogs, cats and horses. Most of its projects involve adapting treatments, currently used by humans, for the animal market. Expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. It listed in London in 2000.
Registrars: Computershare Investor Services PLC

Key Personnel

Independent Non-Executive Director: Julian Heslop
CEO: Ian Page
CFO: Paul Sandland
Independent Non-Executive Director: Lisa Bright
Independent Non-Executive Director: Ishbel Jean Stewart Macpherson
Managing Director: Tony Griffin
Non-Executive Chairman: Alison Platt
Senior Independent Director: Lawson Macartney
Non-Executive Dir: John Shipsey

Contact Details

Address: 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, United Kingdom, CW9 7UA
Phone: +44 (0) 160 681 4730
Fax: +44 (0) 160 681 4731
Website: http://www.dechraplc.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE 100FTSE 350FTSE All-Share
Overseas Listings: BATSLON:DPHL
ISIN: GB0009633180

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

DPH Market Data

Currency UK Pounds
Share Price 3,404.00p
Change Today -62.00p
% Change -1.79 %
52 Week High 5,405.00
52 Week Low 3,110.00
Volume 48,481
Shares Issued 108.39m
Market Cap £3,689.69m
RiskGrade 121

DPH Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
99.75% below the market average99.75% below the market average99.75% below the market average99.75% below the market average99.75% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
21.41% below the market average21.41% below the market average21.41% below the market average21.41% below the market average21.41% below the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Income
90.37% below the market average90.37% below the market average90.37% below the market average90.37% below the market average90.37% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
55.14% above the market average55.14% above the market average55.14% above the market average55.14% above the market average55.14% above the market average
60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 5
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

DPH Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Mar-22 28-Oct-21
Paid 07-Apr-22 19-Nov-21
Amount 12.00p 29.39p

Trades for 30-Jun-2022

Time Volume / Share Price
13:35 160 @ 3,404.00p
13:35 60 @ 3,404.00p
13:35 56 @ 3,404.00p
13:35 82 @ 3,402.00p
13:34 28 @ 3,402.00p

DPH Key Personnel

CEO Ian Page
CFO Paul Sandland

Top of Page